https://www.selleckchem.com/pr....oducts/d-luciferin.h
04), for bleeding and ulceration/erosion than for vascular pattern at day 42 [63% and 65% vs. 33% (n=54); p.001 for both] and at day 98 [78% and 92% vs. 56% (n = 5; p = .007 and p .001]. Global endoscopic remission rates at day 98 were higher in patients treated with infliximab than with cyclosporine [73% vs. 25% (n = 26 and 24); p .001]. In steroid-refractory ASUC patients responding to a second-line medical therapy, endoscopic remission process started with bleeding remission and was not achieved in half the patien
Curtir
Comentario
Compartilhar
